Open Access Open Access  Restricted Access Subscription or Fee Access

Ivermectin: Its Therapeutic Efficacy in the Treatment of COVID-19

Sreeja Nyayakar, Vidhya Suresh, Aju K. Saji

Abstract


Over past 35 years the most commonly used anti-helminthic drug is ivermectin. It has showed good impact in treating the parasitic infections. The drug provides an evidence of immune modulatory and anti-inflammatory actions in vitro animal model. Ivermectin belongs to the class of ivermectin and most widely used as an anti-parasitic agent. It is also used in the treatment of internal nematode infections like onchocerciasis, filariasis, and strongloidiasis. For the treatment of scabies and pediculosis, ivermectin is given through oral route. Ivermectin is a broad spectrum drug having high lipid solubility shows effects on parasites, mycobacterium nematodes etc. The severe acute respiratory symptom corona virus 2, a single stranded RNA virus out brake on December 2019 and spread to various other countries. The in vivo animal study shows ivermectin has board range of antiviral action. Ivermectin, a potential candidate in the treatment of variety of virus including COVID-19 as well as single stranded RNA virus.


Keywords


Covid-19, Ivermectin, Anti helminthic, Treatment, Anti parasitic

Full Text:

PDF

References


Stefanie K, Kumar V, Kim C, John D .The therapeutic potential of ivermectin for covid-19: a review of mechanisms and evidence. Medrxiv 2020:1-17.

Fabio R, Roger L, Juliana D S, Rebouças L Paiva F, Ronaldo N, Lindomar P. Ivermectin: an award-winning drug with expected antiviral activity against covid-19. Journal of controlled release 2020; 329(2021):758-761.

Luana H, Victor SS, Adriano A, Lucindo JQJ, Paulo R M F. Ivermectin: Panacea or true promise for covid-19.excli journal 2020;19:1517-1519.

https://m.chemicalbook.com/ChemicalProductProperty_EN_CB0415655.htm

Emanuele R. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action. Naunyn-Schmiedeberg's Archives of Pharmacology 2020; 393:1153–1156

Khan S, Kuldeep D, Shailesh K P, Mamta P, Ruchi T, Bhoj RS, Ranjit S, D. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrobial 2020; 19(23):1-5.

Carlos C A C, Andres B D M, Fernandez M P, Ruiz C, Mary-Ann R, Mariano R, Mateos C, Jordan I J, Brew F C. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo controlled, randomized clinical trial. Research Square 2020:1-20.

Alberto C, Nunez J, Miguel L, Cervantes M, Antonio O, Juarez G, Ana P R, Murcia J, Josue M. Therapeutic Efficacy of Ivermectin as an Adjuvant in the Treatment of Patients with COVID-19. International Journal of Innovative Science and Research Technology 2020; 5(7):2165-2456.

Faiq I G, Sabeeh M, Hend M S, Basim DD, Marwan M, Mashhadani, Adnan M A, Hassan M A, Mohammed G, Jawad I R. Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management. MedRxiv 2020:1-12.

Juliana C R, Michael SS, Naaz F, Fabio V, Jamie S, Jean J R. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019. CHEST 2021; 159(1):85-92.

Ahmed E, Abdelaziz E, Shaimaa A, Youssef B H, Hafez H M. Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic. Research Square 2020:1-9.

Chinmay S, Podder, Nandini C, Mohim I S, Wasim, Mohosin U H. Outcome of ivermectin treated mild to moderate COVID-19 Cases : a single-center, open-label, randomized controlled study. IMC J Med Sci 2020; 14(2): 1-8.


Refbacks

  • There are currently no refbacks.